Trial Profile
A Phase I, Open-Label, Single-Dose, Two-Part Study to Assess the Pharmacokinetics of Gepotidacin (GSK2140944) in Male and Female Adult Participants With Varying Degrees of Hepatic Impairment and in Matched Control Participants With Normal Hepatic Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Gepotidacin (Primary)
- Indications Bacterial infections; Gonorrhoea; Skin and soft tissue infections; Urinary tract infections
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 01 May 2022 According to a Form 6-K, 2022, company SEC filing, GlaxoSmithKline has changed its name to GSK.
- 23 Jan 2019 Status changed from recruiting to completed.
- 26 Jun 2018 Status changed from not yet recruiting to recruiting.